Company profile: GlycoEra
1.1 - Company Overview
Company description
- Provider of extracellular protein degraders for autoimmune diseases, leveraging its CustomGlycan platform to design bi-functional biologics that selectively degrade circulating or membrane disease-causing proteins, such as autoantibodies, without broadly suppressing the immune system. Offerings include G-LyTACs, a custom glycan engineering platform, and protein degradation therapeutics with applications in oncology.
Products and services
- Protein Degradation Therapeutics: Extracellular therapeutics that selectively target and degrade disease-causing proteins, including autoantibodies, for autoimmune and oncology applications while sparing broad immune suppression
- G-LyTACs: Custom-engineered, bi-functional biologics that degrade circulating or membrane proteins implicated in disease by leveraging engineered glycosylation for highly selective, targeted action
- Custom Glycan Engineering Platform: Proprietary platform that engineers and produces proteins with specific glycosylation patterns to architect biologics that selectively target and degrade disease-causing proteins without broad immune suppression
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to GlycoEra
CB Fleet
HQ: United States
Website
- Description: Provider of feminine care products for personal hygiene and comfort and over-the-counter (OTC) healthcare products addressing common health concerns, serving as a manufacturer, marketer, and distributor.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full CB Fleet company profile →
Idorsia
HQ: Switzerland
Website
- Description: Provider of innovative biopharmaceutical therapies and resources, including daridorexant (QUVIVIQ), a dual orexin receptor antagonist for chronic insomnia, aprocitentan (TRYVIO/JERAYGO), an oral dual endothelin receptor antagonist for resistant hypertension, and a medical information and educational portal for healthcare professionals and patients.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Idorsia company profile →
Axys Pharmaceuticals
HQ: United States
Website
- Description: Provider of discovery, design, and development services for therapeutic small molecules addressing significant markets with major unmet medical needs; collaborates with large pharmaceutical companies to discover therapeutics for chronic diseases.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Axys Pharmaceuticals company profile →
KalVista Pharmaceuticals
HQ: United States
Website
- Description: Provider of oral plasma kallikrein inhibitors for on-demand treatment of hereditary angioedema (HAE), including Sebetralstat being evaluated in the KONFIDENT Phase 3 Trial; developer of oral Factor XIIa inhibitors to prevent thrombosis with reduced bleeding risk; and other oral therapies targeting the kallikrein-kinin system, including HAE. An ophthalmology company with a focus on diabetic macular edema (DME).
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full KalVista Pharmaceuticals company profile →
Faraday Pharma
HQ: United States
Website
- Description: Provider of early-stage therapeutics targeting ischemia-reperfusion injury, led by FDY-5301, a sodium iodide formulation in Phase 3 to reduce injury after myocardial infarction and potentially decrease heart failure and cardiovascular death. Advancing FDY-8801 for cachexia, and running Iocyte AMI-3 Phase 3 in anterior STEMI PCI; Iocyte AMI Phase 2 completed showing cardiac and inflammatory biomarker reductions.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Faraday Pharma company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for GlycoEra
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to GlycoEra
2.2 - Growth funds investing in similar companies to GlycoEra
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for GlycoEra
4.2 - Public trading comparable groups for GlycoEra
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →